To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
Fundamental Research Division
The DRF at the CEA assemble approximately 6,000 scientists since January 2016.
Different greenhouse gases do not have the same levels of persistence in the atmosphere. The calculation of their CO2 equivalent emissions therefore depends on the time periods in question. According to a collaboration led by the LSCE (CEA-CNRS-UVSQ), adjusting these durations will make it possible to better identify the most economically advantageous policies for reducing warming.
Researchers at the CEA-Jacob have reported a new optimized strategy to treat β-thalassemia that uses a lentiviral gene therapy vector.
Researchers at the CEA-Jacob have shown that activation of the PPAR-γ receptor is a relevant therapeutic target for the management of myelofibrosis. This work signals that agonists of PPAR-γ could be introduced into clinical practice.
Thanks to an innovative approach developed by researchers at the Irig, the CEA-Leti and their partners, the identification of phages effective against antibiotic-resistant bacteria has been accelerated and the number of false negatives reduced. This work opens up the possibility of using phage therapy in hospitals!
Scientists from the Institute of Structural Biology (Irig) and their partners have confirmed that the COVID-19 virus can use immune cells to increase its transmission to other cells. They also show that it is possible to inhibit this new mode of transmission of the virus through the use of glycomimetics, i.e. molecules that can mimic the surface “sugars” of the virus.
Researchers from the CEA-Joliot and their partners have studied the efficiency of bio-inspired catalysts at reducing CO2 on the basis of their chemical structure. Their results provide an opportunity to develop catalysts that can be used on a large scale ... as well as reduce the accumulation of CO2 in the atmosphere!
High-level experts from around the world will discuss progress towards achieving energy production from nuclear fusion at an International Atomic Energy Agency (IAEA) meeting next week. The 28th IAEA Fusion Energy Conference (FEC) will take place virtually from 10 to 15 May. It is organized by the IAEA and co-hosted by the ITER Organization and the Government of France through the French Alternative Energies and Atomic Energy Commission (CEA).
Under the impetus of Patrick Landais, the High Commissioner, the FOCUS incentive program has selected the Organoids On a Chip (OOC) project to support interdisciplinary synergies between technological sciences and life sciences within the CEA. The objective is to promote the emergence of breakthrough ideas, concepts or technologies in the biomedical field.
BIAM researchers, together with international partners, have succeeded in developing a contrast agent that improves the accuracy of medical imaging, and that is also capable of treating tumors and delivering localized treatment.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.